Stimulation of metabotropic glutamate (mGlu) 2 receptor and blockade of mGlu1 receptor improve social memory impairment elicited by MK-801 in rats

Journal of Pharmacological Sciences

Volumn 122, Issue 1, 2013, Pages 10-16

  Hikichi, Hirohiko ^a   Kaku, Ayaka ^a   Karasawa, Jun Ichi ^a   Chaki, Shigeyuki ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

mGlu1 receptor antagonist; mGlu2 receptor potentiator; mGlu2 3 receptor agonist; Social memory

Indexed keywords

(3,4 DIHYDRO 2H PYRANO[2,3 B]QUINOLIN 7 YL)(4 METHOXYCYCLOHEXYL)METHANONE; 2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 3' [[(2 CYCLOPENTYL 2,3 DIHYDRO 6,7 DIMETHYL 1 OXO 1H INDEN 5 YL)OXY]METHYL](1,1' BIPHENYL) 4 CARBOXYLIC ACID; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; JNJ 16259685; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; MALE; MEMORY DISORDER; NONHUMAN; RAT; RECOGNITION; SHORT TERM MEMORY; SOCIAL COGNITION; SOCIAL INTERACTION; SOCIAL MEMORY IMPAIRMENT; TREATMENT RESPONSE;

EID: 84878144246     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13036FP     Document Type: Article

References (45)

1. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmüller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett. 1980;20:379-382. (Pubitemid 11160082)
2. Tamminga CA. Schizophrenia and glutamate transmission. Crit Rev Neurobiol. 1998;12:21-36.
3. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301-1308.
4. Nicoletti F, Bockaert J, Collingridge GL, Conn PJ, Ferraguti F, Schoepp DD, et al. Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology. 2011;60:1017-1041.
5. Woolley ML, Pemberton DJ, Bate S, Corti C, Jones DN. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl). 2008;196:431-440.
6. Galici R, Echemendia NG, Rodriguez AL, Conn PJ. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther. 2005;315:1181-1187. (Pubitemid 41635406)
7. Matrisciano F, Tueting P, Maccari S, Nicoletti F, Guidotti A. Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice. Neuropsychopharmacology. 2012;37:929-938.
8. Satow A, Maehara S, Ise S, Hikichi H, Fukushima M, Suzuki G, et al. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl] -nisopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide]. J Pharmacol Exp Ther. 2008;326:577-586.
9. Satow A, Suzuki G, Maehara S, Hikichi H, Murai T, Murai T, et al. Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2, 3,-triazole-4-yl]-2, 3-dihydro-1H-isoindol-1-one. J Pharmacol Exp Ther. 2009;330:179-190.
10. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007;13:1102-1107. (Pubitemid 47517511)
11. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic receptor agonist in rats. Science. 1998;281:1349-1352. (Pubitemid 28406826)
12. Krystal JH, DSouza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, et al. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl). 1999;145:193-204.
13. Kuperberg G, Heckers S. Schizophrenia and cognitive function. Curr Opin Neurobiol. 2000;10:205-210. (Pubitemid 30201113)
14. Nuechterlein KH, Robbins TW, Einat H. Distinguishing separable domains of cognition in human and animal studies: what separations are optimal for targeting interventions? A summary of recommendations from breakout group 2 at the measurement and treatment research to improve cognition in schizophrenia new approaches conference. Schizophr Bull. 2005;31:870-874. (Pubitemid 41437780)
15. Savina I, Beninger RJ. Schizophrenic patients treated with clozapine or olanzapine perform better on theory of mind tasks than those treated with risperidone or typical antipsychotic medications. Schizophr Res. 2007;94:128-138. (Pubitemid 47031590)
16. Shimazaki T, Kaku A, Chaki S. D-Serine and a glycine trans-porter- 1 inhibitor enhance social memory in rats. Psychopharmacology (Berl). 2010;209:263-270.
17. Cartmell J, Monn JA, Schoepp DD. The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing. Eur J Pharmacol. 2000;400:221-224. (Pubitemid 30438730)
18. Galici R, Jones CK, Hemstapat K, Nong Y, Echemendia NG, Williams LC, et al. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther. 2006;318:173-185.
19. Steckler T, Oliveira AF, Van Dyck C, Van Craenendonck H, Mateus AM, Langlois X, et al. Metabotropic glutamate receptor 1 blockade impairs acquisition and retention in a spatial Water maze task. Behav Brain Res. 2005;164:52-60. (Pubitemid 41253732)
20. Harich S, Gross G, Bespalov A. Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology (Berl). 2007;192:511-519. (Pubitemid 46870746)
21. Fell MJ, Svensson KA, Johnson BG, Schoepp DD. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R, 4S, 5S, 6S)-4-amino-2-sulfonylbicyclo [3.1.0]hexane-4, 6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther. 2008;326:209-217. (Pubitemid 351872145)
22. Kingston AE, Ornstein PL, Wright RA, Johnson BG, Mayne NG, Burnett JP, et al. LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology. 1998;37:1-12. (Pubitemid 28300133)
23. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience. 2003;117:697-706. (Pubitemid 36263162)
24. Lewis DA, Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol. 2006;63:1372-1376. (Pubitemid 44547546)
25. Calcagno E, Carli M, Baviera M, Invernizzi RW. Endogenous serotonin and serotonin2C receptors are involved in the ability of M100907 to suppress cortical glutamate release induced by NMDA receptor blockade. J Neurochem. 2009;108:521-532.
26. Dedeurwaerdere S, Wintmolders C, Straetemans R, Pemberton D, Langlois X. Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist. Psychopharmacology (Berl). 2011;214:505-514.
27. Gozzi A, Large CH, Schwarz A, Bertani S, Crestan V, Bifone A. Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology. 2008;33:1690-1703. (Pubitemid 351684709)
28. Hackler EA, Byun NE, Jones CK, Williams JM, Baheza R, Sengupta S, et al. Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation. Neuroscience. 2010;168:209-218.
29. Chin CL, Upadhyay J, Marek GJ, Baker SJ, Zhang M, Mezler M, et al. Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals. J Pharmacol Exp Ther. 2011;336:709-715.
30. Galante M, Diana MA. Group I metabotropic glutamate receptors inhibit GABA release at interneuron-Purkinje cell synapses through endocannabinoid production. J Neurosci. 2004;24:4865-4874. (Pubitemid 38668211)
31. Maejima T, Hashimoto K, Yoshida T, Aiba A, Kano M. Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron. 2001;31:463-475. (Pubitemid 32778564)
32. Varma N, Carlson GC, Ledent C, Alger BE. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J Neurosci. 2001;21:RC188.
33. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev. 2009;89:309-380.
34. Gupta DS, McCullumsmith RE, Beneyto M, Haroutunian V, David KL, Meador-Woodruff JH. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse. 2005;57:123-131. (Pubitemid 41023469)
35. Volk DW, Eggan SM, Lewis DA. Alterations in metabotropic glutamate receptor 1{alpha} and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia. Am J Psychiatry. 2010;167:1489-1498.
36. Erdely HA, Tamminga CA, Roberts RC, Vogel MW. Regional alterations in RGS4 protein in schizophrenia. Synapse. 2006;59:472-479.
37. Melendez RI, Vuthiganon J, Kalivas PW. Regulation of extracellular glutamate in the prefrontal cortex: focus on the cystine glutamate exchanger and group I metabotropic glutamate receptors. J Pharmacol Exp Ther. 2005;314:139-147. (Pubitemid 41065025)
38. Chaki S, Hikichi H. Targeting of metabotropic glutamate receptors for the treatment of schizophrenia. Curr Pharm Des. 2011;17:94-102.
39. Schlumberger C, Schäfer D, Barberi C, Morè L, Nagel J, Pietraszek M, et al. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition. Behav Pharmacol. 2009;20:56-66.
40. Horiguchi M, Huang M, Meltzer HY. Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. Psychopharmacology (Berl). 2011;217:13-24.
41. Jones CA, Brown AM, Auer DP, Fone KC. The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat. Psychopharmacology. 2011;214:269-283.
42. Ago Y, Araki R, Yano K, Kawasaki T, Chaki S, Nakazato A, et al. The selective metabotropic glutamate 2/3 receptor agonist MGS0028 reverses isolation rearing-induced abnormal behaviors in mice. J Pharmacol Sci. 2012;118:295-298.
43. Ago Y, Hiramatsu N, Ishihama T, Hazama K, Hayata-Takano A, Shibasaki Y, et al. The selective metabotropic glutamate 2/3 receptor agonist MGS0028 reverses psychomotor abnormalities and recognition memory deficits in mice lacking the pituitary adenylate cyclase-activating polypeptide. Behav Pharmacol. 2013;24:74-77.
44. Higgins GA, Ballard TM, Kew JN, Richards JG, Kemp JA, Adam G, et al. Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Neuropharmacology. 2004;46:907-917. (Pubitemid 38471944)
45. El-Kouhen O, Lehto SG, Pan JB, Chang R, Baker SJ, Zhong C, et al. Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist. Br J Pharmacol. 2006;149:761-774. (Pubitemid 44748069)